PR Newswire
PHILADELPHIA
, Feb. 5, 2025 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET.
An audio webcast of the event will be available on the Company’s Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Investors:
Shveta Dighe
[email protected]
Media Contact:
Julia Stern
(763) 350-5223
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html
SOURCE Carisma Therapeutics Inc.
